DALLAS, TX / ACCESSWIRE / July 18, 2017 / North American Cannabis Holdings, Inc. (OTC PINK: USMJ) ("USMJ") today announced optimism for the entire medical marijuana sector. The message from Washington D.C. since the Trump Administration took office has been mixed, at best, and, in general, not overly supportive when it comes to federal support of state marijuana legalization. Last week, U.S. Senate Appropriations Committee adopted an amendment on Thursday with a bi-partisan vote to allow veterans to receive recommendations for medical marijuana (See Forbes Cannabis Industry Recap).

Cannabis Legalization Advocacy

USMJ is a veteran-founded cannabis industry company and, in addition to developing a variety of cannabis industry enterprises, USMJ is a regular advocate for marijuana legalization. The Company recently hosted a Fourth of July Holiday Season Social Media Campaign to Rally Support for Marijuana Legalization, encouraging supporters to repost an image of a painting of President George Washington in his hemp field with the label Making America 420 Friendly Again.

USMJ Business Momentum

USMJ business development continues to build momentum. The Company anticipates a major announcement coming soon in conjunction with a contract to co-brand its AmeriCanna Cafe CBD Infused Water. The contract is anticipated to result in a substantial boost to sales in the second half of 2017. The contract is also anticipated to result in a substantial increase to Puration, Inc. (OTC PINK: PURA) ("PURA") sales. PURA provides all cannabis extracts for USMJ beverages and nutritional supplements. USMJ currently reports over $500,000 in annual revenue and PURA has recently signed a letter of intent to acquire an operation expected to produce $1 million in annual revenue.

Learn More About USMJ: growusmj.com
Learn More About PURA: purationinc.com

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.